Beigene Ltd

NASDAQ:BGNEUnited States

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BRUKINSA's ability to provide deep and durable responses with favorable safety for WM patients; BeiGene's ability to further advance its BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax; and BeiGene's plans, commitments, aspirations, and goals under the heading "About BeiGene." Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

05:52 PM EDT, 10/10/2024 (MT Newswires) -- John Oyler, Director, Chief Executive Officer, on October 08, 2024, sold 16,175 shares in Beigene (BGNE) for $3,756,092. Following the Form 4 filing with the SEC, Oyler has control over a total of 47,739,59...

06:40 AM EDT, 09/27/2024 (MT Newswires) -- BeiGene (BGNE) shares were up 3.5% in Friday's premarket activity after it said that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had recognized the "favorable benefit-risk profi...